Patents by Inventor CHRISTOPHER M. RUBINO
CHRISTOPHER M. RUBINO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170143721Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: January 5, 2017Publication date: May 25, 2017Applicants: DURECT CORPORATION, ZOGENIX INC.Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
-
Patent number: 9610286Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: November 1, 2016Date of Patent: April 4, 2017Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9572812Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: GrantFiled: January 14, 2016Date of Patent: February 21, 2017Assignee: DURECT CORPORATIONInventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
-
Publication number: 20170042885Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: November 1, 2016Publication date: February 16, 2017Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9522147Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: August 22, 2016Date of Patent: December 20, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160354365Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: August 22, 2016Publication date: December 8, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160263107Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160256455Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 13, 2016Publication date: September 8, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9433619Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 13, 2016Date of Patent: September 6, 2016Assignee: Pemix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160250207Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 13, 2016Publication date: September 1, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9421200Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 13, 2016Date of Patent: August 23, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9421201Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 20, 2016Date of Patent: August 23, 2016Assignee: Pemis Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160210436Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: ApplicationFiled: January 20, 2015Publication date: July 21, 2016Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Publication number: 20160206618Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: January 14, 2016Publication date: July 21, 2016Applicants: DURECT CORPORATION, ZOGENIX INC.Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
-
Patent number: 9339499Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 17, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9333201Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 10, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9326982Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 3, 2016Assignee: Pemix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160106738Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: December 22, 2015Publication date: April 21, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160106740Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: December 22, 2015Publication date: April 21, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160106739Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: December 22, 2015Publication date: April 21, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson